Cardiff Oncology, Inc. (CRDF) Form 8-K — Aug 11, 2026
Cardiff Oncology reported a Q2 2026 net loss of $9.2 million, or $(0.14) per share, and held approximately $34.5 million in cash, cash equivalents and short-term investments at June 30, 2026 — a figure that excludes the $10 million registered direct offering completed in July. The company believes current cash resources fund operations into the third quarter of 2027. The clinical headline was updated Phase 2 CRDF-004 data presented at ASCO: the selected 30 mg onvansertib plus FOLFIRI/bevacizumab regimen achieved a confirmed objective response rate of 72.2% versus 42.1% for standard of care alone in first-line RAS-mutated metastatic colorectal cancer, with no additive adverse events observed.
Key figures
- Revenue
- $104K Q2 2026 royalty revenue ($145K for the six months ended June 30, 2026)
- Cash Position
- 34500000
- Cash runway
- into the third quarter of 2027
- H1 2025 total opex
- 29389000
- H1 2026 total opex
- 22610000
- Phase2 orr soc arm
- 42.1%
- Pfs hazard ratio ia
- 0.57
- Pfs hazard ratio bicr
- 0.55
- Rd expense decrease h1
- 9400000
- Sga expense increase h1
- 2600000
- Total assets jun30 2026
- 37329000
- Weighted avg shares q2 2026
- 68397000
- Total liabilities jun30 2026
- 10797000
- Stockholders equity jun30 2026
- 26532000
- H1 2025 cash used in operations
- 21100000
- H1 2026 cash used in operations
- 24100000
- Phase2 orr onvansertib 30mg arm
- 72.2%
- Patients on trial jun23 2026 datacut
- 12
- Registered direct offering july 2026
- 10000000
Price after filing
Close on the filing date to close N calendar days later (from $0.99). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.